The ALS Therapy Development Institute (ALS TDI) has developed a tool that maps ALS clinical trials globally, using technology from Esri.
Dubbed ALS Trial Navigator, the tool is designed to streamline the process by which individuals with ALS and their caretakers locate ongoing ALS trials.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The tool offers an interactive map that allows users to identify trial locations relevant to their condition.
It also generates a personalised map based on user preferences and the current state of their ALS, enhancing the search for suitable trials.
The distinct feature of the tool is its capability to match ALS patients with the most appropriate trials. It considers factors such as progression of the disease, genetics and location, alongside trial requirements and enrolment status.
The ALS Trial Navigator also includes the Trial Browser and the Guided Trial Finder.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThese features enable patients to sift through a global list of trials and apply filters like placebo ratio, genetics and country.
Additionally, by entering personal details such as symptom onset and travel willingness, users receive a tailored list of trials matching their eligibility and preferences.
The tool also serves as an informative platform for ALS researchers and advocates to gain insights into the clinical trial landscape.
ALS TDI community engagement director Dr Nadia Sethi said: “ALS Trial Navigator helps people living with ALS, those that might face it in the future, and researchers looking to enrol trials by educating the community and providing information about current studies all around the world.
“With the information in this tool, people can start thinking about the aspects of research studies that might matter most to them and generate a list of trials that might be a fit for them so that they can have an informed discussion with their clinicians.”
